AN2 Therapeutics Current Cash

AN2 Therapeutics's current cash stands at $53M as of March 2026. That compares with $20M in the prior-year period — up 167.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

AN2 Therapeutics reported $53M in current cash versus $20M a year earlier — a 167.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $20M in the prior-year period — up 167.6% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how AN2 Therapeutics's current cash evolved across reporting periods, while the comparison chart places ANTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.